SCHEMBL4483505

SCHEMBL4483505

[CH]c1nc(C(=O)OCC)cs1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.64
NPC1 O15118 6/20 0.64
MAPT P10636 6/20 0.64
ALDH1A1 P00352 3/20 0.64
MEN1 O00255 1/20 0.64
KMT2A Q03164 1/20 0.64
CYP1A2 P05177 2/20 0.57
CYP2C19 P33261 1/20 0.57
SMN1; SMN2 Q16637 5/20 0.55
GAA P10253 4/20 0.55
POLB P06746 1/20 0.54
PKM P14618 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54
TDP1 Q9NUW8 1/20 0.52
HSP90AA1 P07900 2/20 0.51
MAPK1 P28482 1/20 0.48
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
EGFR P00533 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13144514 0.82 MAPT (0.70) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL914552 0.82 RAB9A (0.68) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL19208916 0.81 RAB9A (0.66) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL163667 0.81 RAB9A (0.66) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL285573 0.81 RAB9A (0.66) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL9454202 0.81 RAB9A (0.66) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL1438508 0.81 RAB9A (0.66) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL3001536 0.79 RAB9A (0.64) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL220846 0.79 RAB9A (0.97) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL13075225 0.79 RAB9A (0.64) RAB9ANPC1MAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622464-B2 Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases GLAXO GROUP LIMITED (GB) 2009-11-24 US disclosed
EP-1487828-B1 MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES GLAXO GROUP LTD (GB) 2008-11-05 EP disclosed
US-20060063765-A1 Novel compounds GLAXO GROUP LIMITED (GB) 2006-03-23 US disclosed
EP-1487828-A2 MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES GLAXO GROUP LIMITED (GB) 2004-12-22 EP disclosed
WO-2003082861-A2 MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063765-A1 Novel compounds CCR3, NSUN3, CCR1 RAB9A 1235/4885NPC1 931/4885MAPT 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.